Drug toxicity remains one of the main causes of compound attrition in the drug development process. Compounds displaying organ, mechanism-based or off-target toxicity are just some of the safety issues that have contributed to drug development failures, and the need for robust early drug safety screening in an integrative manner is clear.This meeting will bring together a range of international experts from both industry and academia to present the new technologies and their applications in early drug safety assessment.
Reducing Attrition through Early Assessment of Drug Safety
13 March 2014, London, United Kingdom
Introduction
Venue
National Heart and Lung Institute
Lecture Theatre, National Heart and Lung Institute, Dovehouse Street, Kensington, London, United Kingdom
Organised by
Society for Medicines Research
Contact information
Related events
8th International Conference on Nanomaterials Science and Mechanical Engineering
7 July 2026 08:00 - 10 July 2026 18:00, Aveiro, Portugal
The 59th Annual International Meeting of the ESR Spectroscopy Group of the 91AV
13 April 2026 15:00 - 16 April 2026 23:00, Colchester, United Kingdom
6th International Conference on Emerging Advanced Nanomaterials
16 November 2026 08:00 - 20 November 2026 18:00, Newcastle, Australia
Chemical Biology meets Drug Discovery
14 September 2026 09:30 - 15 September 2026 16:30, Cambridge, United Kingdom
Search
Advertisement
Spotlight
Explore
Membership
